DILIC
NBIX icon

Dai-ichi Life Insurance Company’s Neurocrine Biosciences NBIX Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Buy
14,741
+1,763
+14% +$262K 0.06% 252
2026
Q1 		$1.71M Hold
12,978
– – 0.05% 273
2025
Q4 		$1.84M Hold
12,978
– – 0.05% 279
2025
Q3 		$1.82M Buy
12,978
+2,119
+20% +$287K 0.05% 283
2025
Q2 		$1.36M Sell
10,859
-29,853
-73% -$3.42M 0.04% 317
2025
Q1 		$4.5M Sell
40,712
-952
-2% -$121K 0.13% 164
2024
Q4 		$5.69M Sell
41,664
-455
-1% -$56.3K 0.16% 146
2024
Q3 		$4.85M Sell
42,119
-6,358
-13% -$872K 0.12% 164
2024
Q2 		$6.67M Buy
48,477
+27,529
+131% +$3.78M 0.16% 139
2024
Q1 		$2.89M Buy
+20,948
New +$2.86M 0.07% 254
2017
Q1 		– Sell
-16,677
Closed -$645K – 563
2016
Q4 		$645K Buy
+16,677
New +$755K 0.02% 433

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dai-ichi Life Insurance Company's NBIX Position: Q2 2026 in Review

Dai-ichi Life Insurance Company increased its Neurocrine Biosciences (NBIX) stake by 14% in Q2 2026, buying an estimated $262K and bringing the position to 14,741 shares worth $2.48M. The position accounts for 0.06% of the portfolio, ranked #252.

Dai-ichi Life Insurance Company first reported a position in NBIX in Q4 2016 and has held it in 11 quarters since. The position peaked at $6.67M in Q2 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Dai-ichi Life Insurance Company held 14,741 shares of Neurocrine Biosciences worth $2.48M as of Q2 2026.
  • Dai-ichi Life Insurance Company bought 1,763 Neurocrine Biosciences shares in Q2 2026, an estimated $262K.
  • Neurocrine Biosciences made up 0.06% of Dai-ichi Life Insurance Company's portfolio in Q2 2026, its #252 holding.
  • Dai-ichi Life Insurance Company first reported a position in Neurocrine Biosciences in Q4 2016 and has held it in 11 quarters since.
  • Dai-ichi Life Insurance Company's Neurocrine Biosciences position peaked at $6.67M in Q2 2024.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Dai-ichi Life Insurance Company's 13F filing for Q2 2026, filed 12 Aug 2026.